Universal CAR-T
Showing 1 - 25 of >10,000
Multiple Myeloma in Remission Trial in Shenzhen, Haikou (MM-specific universal CAR T cells)
Recruiting
- Multiple Myeloma in Remission
- MM-specific universal CAR T cells
-
Shenzhen, Guangdong, China
- +1 more
Aug 23, 2023
Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)
Recruiting
- Acute Myeloid Leukemia
- CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Diffuse Scleroderma Trial in Shanghai (BRL-301)
Recruiting
- Systemic Lupus Erythematosus (SLE)
- +5 more
- BRL-301
-
Shanghai, Shanghai, ChinaShanghai ChangZheng hospital
May 7, 2023
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- U-CAR-T Cells (LstCAR019)
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
Systemic Lupus Erythematosus (SLE) Trial (BRL-301)
Not yet recruiting
- Systemic Lupus Erythematosus (SLE)
- BRL-301
- (no location specified)
Aug 13, 2023
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- UCAR-T Cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022
Systemic Lupus Erythematosus Trial (CD19 Universal CAR-?d T Cells)
Not yet recruiting
- Systemic Lupus Erythematosus
- CD19 Universal CAR-γδ T Cells
- (no location specified)
Oct 24, 2023
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +3 more
- Universal CD7-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 17, 2023
B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)
Recruiting
- B Cell Malignancies
- Universal CD19-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))
Recruiting
- Advanced Solid Tumors
- Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
-
Hangzhou, ChinaFirst affiliated hospital, School of Medicine, Zhejiang Universi
Aug 3, 2023
B-Cell Leukemia, B Cell Lymphoma Trial in Kunming (anti-CD19 UCAR-T injection)
Recruiting
- B-Cell Leukemia
- B Cell Lymphoma
- anti-CD19 UCAR-T injection
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Apr 21, 2022
T-cell Leukemia, T-cell Lymphoma Trial in ChongQing (CD7 UCAR-T cells, Fludarabine, Cytoxan)
Recruiting
- T-cell Leukemia
- T-cell Lymphoma
- CD7 UCAR-T cells
- +3 more
-
ChongQing, Chongqing, ChinaDepartment of Hematology, Xinqiao Hospital
Jun 21, 2021
AML Trial in Yanda (CAR-?dT)
Recruiting
- AML
- CAR-γδT
-
Yanda, Hebei, ChinaHebei yanda Ludaopei Hospital
Mar 11, 2021
T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)
Withdrawn
- T-cell Acute Lymphoblastic Leukemia
- T-lymphoblastic Lymphoma
- Target CD7 CAR-T cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Nov 23, 2022
Relapsed/Refractory Multiple Myeloma Trial in United States (genetic, biological, drug)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- ALLO-715
- +4 more
-
Gilbert, Arizona
- +11 more
Feb 18, 2022
CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level
Recruiting
- CAR
- +2 more
- ThisCART19A with Dose Level 1
- ThisCART19A with Dose Level 2
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jan 18, 2023
AML Trial in Wuhan (CAR--?dT cells)
Recruiting
- AML
- CAR--γδT cells
-
Wuhan, Hubei, ChinaTongji Hospital
May 24, 2022
Hematological Malignancies Trial (Anti-CD7 CAR-T)
Not yet recruiting
- Hematological Malignancies
- Anti-CD7 CAR-T
- (no location specified)
Jul 8, 2022
Safety and Efficacy of TCR-like CAR-T Trial in Nanjing (TCR-like CAR-T)
Recruiting
- Safety and Efficacy of TCR-like CAR-T
- TCR-like CAR-T
-
Nanjing, Jiangsu, ChinaZhongda hospital
Jul 26, 2023
Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)
Recruiting
- Multiple Myeloma
- APRIL-BAFF-Bicephali CAR-T cells
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 14, 2023
B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)
Withdrawn
- B-cell Lymphoma
- B-cell Leukemia
- anti-CD19 UCAR-NK cells
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
Gastric Cancer, Colon Cancer, Pancreas Cancer Trial in Nanchang (CEA CAR-T cells)
Recruiting
- Gastric Cancer
- +6 more
- CEA CAR-T cells
-
Nanchang, Jiangxi, ChinaThe First Affiliated Hospital of Nanchang University
Aug 23, 2023
CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)
Recruiting
- CAR
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 27, 2022
CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study
Not yet recruiting
- Lymphoma
- Chimeric Antigen Receptor
- (no location specified)
Oct 24, 2023
Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)
Recruiting
- Gastric Cancer
- +6 more
- CEA-targeted CAR-T cells
-
Taiyuan, Shanxi, China
- +1 more
Aug 24, 2023